The private-credit arm of Guggenheim Investments has employed a novel tool to attract institutional investors to its newest fund as it contends with fierce fundraising competition from other ...

Guggenheim Securities adjusted its price target for Immunovant shares, listed on (NASDAQ:IMVT), to $44.00, a decrease from the previous $46.00, while sustaining a Buy rating on the stock. Currently ...

DAVOS, Switzerland, Jan 20 (Reuters) - Guggenheim Partners' chief investment officer forecast on Monday that the U.S. Federal Reserve is likely to cut interest rates roughly every quarter in 2025 ...

Guggenheim has outlined four major scenarios ... In other recent news, Piper Sandler, a prominent investment bank, has provided an update on potential catalysts for biotechnology companies up ...

NEW YORK, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Guggenheim Investments today announced that certain closed-end funds have declared their distributions. The table below summarizes the distribution ...

Consult a professional regarding your specific legal or tax matters. Guggenheim Investments is the global asset management and investment advisory division of Guggenheim Partners, LLC ...

Guggenheim analyst Shahriar Pourreza maintained a Hold rating on Spire (SR – Research Report) today and set a price target of $67.00. The ...

Guggenheim analyst Robert Drbul reiterated a Buy rating on Levi Strauss & Co (LEVI – Research Report) today and set a price target of ...